Lipoprotein (a): a Historical Appraisal

Overview

Journal J Lipid Res

Publisher Elsevier

Specialty Biochemistry

Date 2016 Nov 9

PMID 27821413

Citations 27

Authors

Karam M Kostner

Gert M Kostner

Affiliations

Soon will be listed here.

Abstract

Initially, lipoprotein (a) [Lp(a)] was believed to be a genetic variant of lipoprotein (Lp)-B. Because its lipid moiety is almost identical to LDL, Lp(a) has been deliberately considered to be highly atherogenic. Lp(a) was detected in 1963 by Kare Berg, and individuals who were positive for this factor were called Lpa Lpa individuals were found more frequently in patients with coronary heart disease than in controls. After the introduction of quantitative methods for monitoring of Lp(a), it became apparent that Lp(a), in fact, is present in all individuals, yet to a greatly variable extent. The genetics of Lp(a) had been a mystery for a long time until Gerd Utermann discovered that apo(a) is expressed by a variety of alleles, giving rise to a unique size heterogeneity. This size heterogeneity, as well as countless mutations, is responsible for the great variability in plasma Lp(a) concentrations. Initially, we proposed to evaluate the risk of myocardial infarction at a cut-off for Lp(a) of 30-50 mg/dl, a value that still is adopted in numerous epidemiological studies. Due to new therapies that lower Lp(a) levels, there is renewed interest and still rising research activity in Lp(a). Despite all these activities, numerous gaps exist in our knowledge, especially as far as the function and metabolism of this fascinating Lp are concerned.

Citing Articles

Living with Elevated Lipoprotein(a) Levels: The Experiences of Patients and Caregivers.

Steinhagen-Thiessen E, Daccord M, Print E, Wang Y, Shipton J, Rijken I Patient Prefer Adherence. 2025; 19:395-405.

PMID: 40008374 PMC: 11853138. DOI: 10.2147/PPA.S478623.

Clinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long-acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double-blind, placebo-controlled phase Ia and Ib/II studies.

Jiang J, Xu L, Chai L, Guan X, Zhang L, Liu H Clin Transl Sci. 2024; 17(11):e70061.

PMID: 39498965 PMC: 11536336. DOI: 10.1111/cts.70061.

Lipoprotein (a) as a Cardiovascular Risk Factor in Controversial Clinical Scenarios: A Narrative Review.

Abdalla H, Mahmoud A, Khedr A, Farina J, Scalia I, Abbas M Int J Mol Sci. 2024; 25(20).

PMID: 39456811 PMC: 11507037. DOI: 10.3390/ijms252011029.

Lipoprotein(a) in Children and Adolescents: Risk or Causal Factor for Cardiovascular Disease? A Narrative Review.

Capra M, Biasucci G, Banderali G, Pederiva C Int J Mol Sci. 2024; 25(16).

PMID: 39201505 PMC: 11354582. DOI: 10.3390/ijms25168817.

Comparative Analysis of Atherogenic Lipoproteins L5 and Lp(a) in Atherosclerotic Cardiovascular Disease.

Akyol O, Yang C, Woodside D, Chiang H, Chen C, Gotto A Curr Atheroscler Rep. 2024; 26(7):317-329.

PMID: 38753254 PMC: 11192678. DOI: 10.1007/s11883-024-01209-3.

References

Dieplinger H, Utermann G . The seventh myth of lipoprotein(a): where and how is it assembled?. Curr Opin Lipidol. 1999; 10(3):275-83. DOI: 10.1097/00041433-199906000-00010. View

Kostner K, Maurer G, Huber K, Stefenelli T, Dieplinger H, Steyrer E . Urinary excretion of apo(a) fragments. Role in apo(a) catabolism. Arterioscler Thromb Vasc Biol. 1996; 16(8):905-11. DOI: 10.1161/01.atv.16.8.905. View

Steinberg D, Witztum J . Oxidized low-density lipoprotein and atherosclerosis. Arterioscler Thromb Vasc Biol. 2010; 30(12):2311-6. DOI: 10.1161/ATVBAHA.108.179697. View

Klatt P, Esterbauer H . Oxidative hypothesis of atherogenesis. J Cardiovasc Risk. 1996; 3(4):346-51. DOI: 10.1177/174182679600300402. View

Graham M, Viney N, Crooke R, Tsimikas S . Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. J Lipid Res. 2015; 57(3):340-51. PMC: 4767000. DOI: 10.1194/jlr.R052258. View

Parson W, Kraft H, Niederstatter H, Lingenhel A, Kochl S, Fresser F . A common nonsense mutation in the repetitive Kringle IV-2 domain of human apolipoprotein(a) results in a truncated protein and low plasma Lp(a). Hum Mutat. 2004; 24(6):474-80. DOI: 10.1002/humu.20101. View

Marth E, Cazzolato G, Bittolo Bon G, AVOGARO P, Kostner G . Serum concentrations of Lp(a) and other lipoprotein parameters in heavy alcohol consumers. Ann Nutr Metab. 1982; 26(1):56-62. DOI: 10.1159/000176544. View

Fredrickson D, Levy R, Lees R . Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med. 1967; 276(3):148-56 contd. DOI: 10.1056/NEJM196701192760305. View

Krempler F, Kostner G, Roscher A, Haslauer F, Bolzano K, SANDHOFER F . Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man. J Clin Invest. 1983; 71(5):1431-41. PMC: 437007. DOI: 10.1172/jci110896. View

10.

Tsimikas S, Viney N, Hughes S, Singleton W, Graham M, Baker B . Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet. 2015; 386(10002):1472-83. DOI: 10.1016/S0140-6736(15)61252-1. View

11.

Kostner G, Wo X, Frank S, Kostner K, Zimmermann R, Steyrer E . Metabolism of Lp(a): assembly and excretion. Clin Genet. 1998; 52(5):347-54. DOI: 10.1111/j.1399-0004.1997.tb04352.x. View

12.

McLean J, Tomlinson J, Kuang W, Eaton D, Chen E, Fless G . cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987; 330(6144):132-7. DOI: 10.1038/330132a0. View

13.

Kronenberg F, Steinmetz A, Kostner G, Dieplinger H . Lipoprotein(a) in health and disease. Crit Rev Clin Lab Sci. 1996; 33(6):495-543. DOI: 10.3109/10408369609080056. View

14.

Kronenberg F, Trenkwalder E, Lingenhel A, Friedrich G, Lhotta K, Schober M . Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. J Lipid Res. 1997; 38(9):1755-63. View

15.

Walton K, Hitchens J, Magnani H, Khan M . A study of methods of identification and estimation of Lp(a) lipoprotein and of its significance in health, hyperlipidaemia and atherosclerosis. Atherosclerosis. 1974; 20(2):323-46. DOI: 10.1016/0021-9150(74)90016-1. View

16.

Chennamsetty I, Claudel T, Kostner K, Trauner M, Kostner G . FGF19 signaling cascade suppresses APOA gene expression. Arterioscler Thromb Vasc Biol. 2012; 32(5):1220-7. DOI: 10.1161/ATVBAHA.111.243055. View

17.

Kostner K, Kostner G . Lipoprotein(a): still an enigma?. Curr Opin Lipidol. 2002; 13(4):391-6. DOI: 10.1097/00041433-200208000-00006. View

18.

Albers J, Wahl P, Hazzard W . Quantitative genetic studies of the human plasma Lp(a) lipoprotein. Biochem Genet. 1974; 11(6):475-86. DOI: 10.1007/BF00486079. View

19.

Utermann G, Menzel H, Kraft H, Duba H, Kemmler H, Seitz C . Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma. J Clin Invest. 1987; 80(2):458-65. PMC: 442258. DOI: 10.1172/JCI113093. View

20.

Rifai N, Ma J, Sacks F, Ridker P, Hernandez W, Stampfer M . Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians' Health Study. Clin Chem. 2004; 50(8):1364-71. DOI: 10.1373/clinchem.2003.030031. View